Turn Therapeutics (NASDAQ:TTRX) Releases Quarterly Earnings Results

Turn Therapeutics (NASDAQ:TTRX) announced its earnings results on Thursday. The company reported ($0.07) EPS for the quarter, Zacks reports.

Turn Therapeutics Stock Performance

NASDAQ:TTRX traded down $0.35 during mid-day trading on Thursday, hitting $4.05. 21,844 shares of the company’s stock traded hands, compared to its average volume of 945,030. Turn Therapeutics has a 1 year low of $3.65 and a 1 year high of $26.50.

Insider Activity at Turn Therapeutics

In other Turn Therapeutics news, insider Abraham Chesed purchased 14,286 shares of the stock in a transaction on Thursday, October 23rd. The stock was bought at an average price of $4.60 per share, for a total transaction of $65,715.60. Following the acquisition, the insider directly owned 1,447,268 shares of the company’s stock, valued at $6,657,432.80. This represents a 1.00% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available at this link.

Turn Therapeutics Company Profile

We are a pharmaceutical and medical device development company built around a proprietary platform technology designed to enhance drug performance. Our patented mixing process — commercially referred to as PermaFusion™ (“PermaFusion”) — enables stable suspension of polar, water-soluble active pharmaceutical ingredients (“APIs”) in oil-based carriers without the use of emulsifiers.